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Primary hyperaldosteronism, is a well-known cause of secondary hypertension, mostly
idiopathic hypertension or arising from aldosterone-producing adenomas. It is charac-
terized with resistant hypertension, hypokalemia and metabolic alkalosis related with
aldosterone production excess and plasma renin activity suppression. Hypokalemic
rhabdomyolysis usually presents with muscle pain, cramps, fatigability and generalized
weakness. Rhabdomyolysis due to hypokalemia is a rare complication of primary
hyperaldosteronism reported within a limited number of cases in medical literature.
Diagnosis and treatment of primary hyperaldosteronism is fundamentally important
because of the probability of certain cure with accurate surgery. Here, we report a 38-
year-old female with hypertension related with primary hyperaldosteronism who pre-
sented with rhabdomyolysis most likely due to profound hypokalemia.1. Introduction
Primary hyperaldosteronism, is a well-known cause of sec-
ondary hypertension, which is characterized with resistant hy-
pertension, hypokalemia and metabolic alkalosis, associated with
plasma renin activity suppression and aldosterone production
excess[1]. In the case of severe hypokalemia, muscle weakness,
cramping, headaches, palpitations and polyuria may be seen. In
order to make a proper diagnosis, a high index of suspicion is
needed[2]. Rhabdomyolysis is a rare complication of primary
hyperaldosteronism reported within a limited number of cases[3–
6]. Here we report a case of primary aldosteronism presented
with rhabdomyolysis due to hypokalemia.
2. Case presentation
A 38-year-old female was admitted to emergency department
with generalized muscle weakness. Her relatives reported an
inability to walk unassisted since 10 days. Medical history was
unremarkable except metformin use started 1 week ago by aninternal specialist with the diagnosis of type 2 diabetes mellitus
(DM). Loss of appetite and sustained vomitting were present.
The patient was obese with a body mass index of 32, found
dehydrated and hypertensive (blood pressure was 190/
110 mmHg) at clinical examination. Blood tests revealed hy-
perglycemia of 237 mg/dL (reference ranges of 70–115),
metabolic alkalosis of pH 7.51, pO2 57.2 mmHg, pCO2
36.1 mmHg and cHCO3 28.7 mmol/L, severe hypokalemia
(1.6 mmol/L, reference ranges of 3.3–5.5), mild renal insufﬁ-
ciency (urea 67 mg/dL, reference ranges of 0–50 and creatinine
1.58 mg/dL, reference ranges of 0–1.2), creatine phosphokinase
and lactate dehydrogenase elevation (7666 IU/L, reference
ranges of 0–167 and 534 IU/L, reference ranges of 140–280,
respectively). She denied any other medication usage including
insulin and herbal medicine. Based upon these clinical features,
hypokalemia due to gastrointestinal loss and hypokalemia
induced rhabdomyolysis were suspected as ﬁrst diagnosis. After
treatment with hydration and potassium replacement, muscle
weakness was ameliorated dramatically and the blood glucose
was controlled by basal-bolus insulin therapy. A series of lab-
oratory examinations were performed for differential diagnosis
of hypokalemia and hypertension. Twenty-four-hour urinary
potassium excretion was 20.1 mEq. The overnight 1 mg dexa-
methasone screening test for Cushing's Syndrome yielded a
suppressible plasma cortisol level of 1.79 mg/dL. Thyroid
function tests were normal. Plasma renin activity (PRA) was
suppressed (0.2 ng/mL/h, reference ranges of 0.5–1.9) whilearticle under the CC BY-NC-ND license (http://
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values (167.3 pg/mL, reference ranges of 10–160) and the ratio
of PAC/PRA was 83 ng/dL/ng/mL/h. The patient underwent an
abdominal computed tomography (CT) scan, which revealed
two nodular lesions sized 27 and 20 mm in the right adrenal
gland (Figure 1). Spironolactone treatment provided an excellent
improvement in her general condition so that the patient refused
surgical removal. She remains on treatment with spironolactone
of 50 mg/day, metformin of 2 g/day and biphasic insu¨lin of
3 × 20 units/day.Figure 1. Nodular lesions sized 27 and 20 mm in the right adrenal gland.3. Discussion
Here, we report a case of primary hyperaldosteronism pre-
sented with rhabdomyolysis due to profound hypokalemia. Po-
tassium is the most abundant cation in the body which is
predominantly (98%) restricted to the intracellular compartment
and serum level is regulated around a narrow range of 3.5–
5.0 mmol/L. Insulin and catecholamines are physiological short-
term regulators that act in a shift of potassium and deposit it
primarily in the liver and striated muscle cells. b2-stimulation
results in a shift of potassium into the cell, while a-stimulation
has an opposite effect[7].
The kidney is the primary actor in long-term potassium
homoeostasis by matching potassium intake with its excretion.
The ﬁltered potassium is largely reabsorbed by proximal
nephron segments and again excreted by distal segments. The
secretion of potassium in these nephron segments is indirectly
but tightly coupled to sodium reabsorption[8].
Hypokalemia is a common electrolyte disorder encountered
in clinical practice, that may result from insufﬁcient potassium
intake, shift to intracellular space from extracellular space or
excessive loss either renal or extrarenal. Intake of drugs
including b2-mimetics, barium, chloroquine known to cause
internal cellular potassium shift was excluded. Insulin adminis-
tration might be reasonable when the recent diagnosis of DM
was taken in account, but both patient and her relatives denied
insulin usage. Normal thyroid function tests and negative family
history removed the prediagnosis of acquired and/or familial
hypokalemic periodic paralysis. Gastrointestinal losses may be
the underlying cause of hypokalemia. The patient reported
sustained vomitting may result from stress or metformin intol-
erance. In further investigation 24 h urinary potassium excretion
was found at some degree confusing. Usually low urinarypotassium concentrations <20 mEq/L favour extrarenal ﬂuid
losses such as diarrhoea, vomitting. Besides concentrations
>40 mEq/L are considered compatible with urinary losses such
as mineralocorticoid excess, Bartter's syndrome[7]. The
concentration of urinary potassium lower than expected in
primary hyperaldosteronism may be interpreted as a
compensatory effect of kidneys to the sustained vomiting in
presented case.
Rhabdomyolysis is a rare complication of primary hyper-
aldosteronism reported within a limited number of cases in
medical literature[3–6]. The exact mechanism of rhabdomyolysis
remains obscure, but hypokalemia is considered causative
derangement via inducing inadequate vasodilatation of
arterioles and capillaries that perfuse exercising muscle,
suppression of glycogen synthesis and storage and deranged
ion transport across the cell membrane[9]. The main clinical
manifestations of hypokalemic rhabdomyolysis are muscle
pain, cramps, fatigability and generalized weakness as seen in
our patient. Although a large series of pH reported severe
muscle weakness to be a classic clinical manifestation that is
usually related to coexistent hypokalemia in another review
study of 30 patients, ﬁndings were on the contrary[10,11].
Overall majority of patients with pH tend to be normokalemic[12].
Hyperglycemia was another confounding factor in our pa-
tient's clinical picture. Chow et al. described a 70-year-old male
diagnosed as having Conn's syndrome, hypokalemia, rhabdo-
myolysis and mild hyperglycemia[5]. Correction of hypokalemia
resolved rhabdomyolysis rapidly and hyperglycemia reversed by
deﬁnite resection of the aldosterone secreting adenomas[5]. A
signiﬁcant inverse relationship as lower potassium values are
associated with higher glucose values which was demonstrated
previously[13]. The exact mechanism by which hypokalemia
may cause glucose intolerance is still not known, but it is
probably related to defects in insulin release or insulin
sensitivity. It is interesting to note that angiotensin converting
enzyme inhibitors and angiotensin II receptor antagonists
(angiotensin receptor blockers) drugs that results in an increase
in serum K+, which has the lowest rates of new-onset diabetes
and has been advocated as improve insulin sensitivity. The ev-
idence of the importance of hypokalemia of data from studies
over the past 40 years suggest that K+ replacement should
minimize the occurrence of new-onset diabetes observed with
thiazide diuretics[14]. Our patient was an obese female prone to
impaired glucose tolerance with a positive family history of
DM, but it would not be completely wrong to speculate a
triggering effect of hypokalemia in newly onset hyperglycemia.
Primary aldosteronism is a well-known cause of secondary
hypertension resulted from excessive or inappropriately elevated
aldosterone production from the adrenals[1]. Although reported
prevalence varies considerably between different studies,
depending on patient selection, diagnostic methodology
employed and severity of arterial hypertension, it is estimated to
be 4.6%–16.6% in unselected hypertensive populations and
17%–23% in patients with resistant hypertension[15]. Primary
hyperaldosteronism may exist in several forms and the most
common forms are idiopathic hyperaldosteronism (60%–66%)
and aldosterone-producing adenoma (APA) (30%–35%). The
remaining forms including primary adrenal hyperplasia, familial
hyperaldosteronism syndrome type 1 or 2, adrenocortical
carcinoma, or ectopic aldosterone production are seen extremely
rare[2]. Screening should be considered in the states like
hypertension and hypokalemia, resistant and severe hypertension,
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young age (<20 years), family history of early onset hypertension
or stroke at age<40, and in hypertensive patients with a ﬁrst degree
relatives of those with primary hyperaldosteronism[16]. Due to the
lack of speciﬁc symptoms and signs, clinician's awareness is of
critical importance in diagnose, hypokalemia itself, while help in
recognizing the disease is not required, just only 9%–37% of
patients with plasma aldosterone (PA) present with
hypokalemia[2]. Presence of both hypokalemia and hypertension
in a young patient marked the diagnosis of hyperaldosteronism,
in presented case. The biochemical hallmarks of primary
hyperaldosteronism are the high aldosterone, and the low renin.
The initial screening test calculates the ratio of PAC/PRA after
correcting hypokalemia if present. The ratio of aldosterone to
PRA expressed in ng/dL and ng/mL/h, respectively, which
exceeds 30 and indicates the diagnosis of PA[17]. Conﬁrmatory
test is strongly recommended with intravenous saline loading,
oral sodium loading and the ﬂudrocortisone suppression test in
order to exclude misdiagnoses derived from laboratory-
dependent thresholds and we skipped that step when we consid-
ered the general status of patient suffered[1]. Finally CT scan
revealed two nodular lesions sized 27 and 20 mm in the right
adrenal gland. The patient was opposite to another more
intervention including adrenal venous sampling and/or
adenomectomy and at that point, medical treatment with
aldosterone antagonist agent spironolactone was prescribed based
on the reported data that unilateral macroadenomas (>1 cm),
detected by CT is highly suggestive for (APA) in the cases of
PA[18]. Although treatment of choice for patients diagnosed with
APA or unilateral hyperplasia is unilateral laparoscopic
adrenalectomy[1], some authors arguing for ﬁrst-choice therapy of
PA should be based on long-term administration of low-dose
mineralocorticoid receptor antagonists (spironolactone, epler-
enone) and the cause of PA is suspected to be the continuum of
low-renin hypertension, regardless of the morphological type of
PA[19]. Our patient was discharged well-feeling with spironolactone
(50mg/day), metformin (2 g/day) and biphasic insulin 3 × 20 units/
day. Left adrenalectomy might have a curable, at least ameliorated
effect on her blood pressure and blood glucose levels.
4. Conclusion
We reported a case with primary aldosteronism not only with
severe hypertension but also complicated with rhabdomyolysis,
providing an important lesson to be aware about the whole
clinical picture. Diagnosis of secondary causes of hypertension
is signiﬁcantly important which can cause the probability of
certain cure with accurate surgery.
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